Table 1.

Plasma Pharmacokinetic Parameters^§

Drug¶	Treatment#	λz	T½	Tmax	Cmax	AUC0-∞	AUMC0-∞	MRT0-∞	Clt	Vd
PTX	SOL	0.66 ± 0.13	1.05 ± 0.33	1	146 ± 14.37	508.74 ± 10.81	825.39 ± 22.71	1.62 ± 0.88	0.04 ± 0.01	0.06 ± 0.03
PTX	TAR NP	0.36 ± 0.07 *	1.92 ± 0.26	1	107.04 ± 11.04	497.60 ± 17.46	1364.85 ± 31.64 ***	2.74 ± 0.75	0.040 ± 0.02	0.11 ± 0.09
PTX	NON NP	0.34 ± 0.10**	2.06 ± 0.50	1	102.48 ± 16.84	436.48 ± 12.36**/‡	1201.23 ± 29.04***/‡‡‡	2.75 ± 0.77	0.05 ± 0.01	0.13 ± 0.09
LON	SOL	0.42 ± 0.16	1.67 ± 1.32	1	185.33 ± 21.99	768.80 ± 24.75	1815.05 ± 24.52	2.36 ± 0.64	0.10 ± 0.02	0.25 ± 0.11
LON	TAR NP	0.17 ± 0.09	4.16 ± 1.87*	1	207.32 ± 27.81	1316.01 ± 33.07***	5761.99 ± 34.85***	4.38 ± 1.01***	0.06 ± 0.03	0.27 ± 0.18
LON	NON NP	0.18 ± 0.12	3.92 ± 1.42	1	183.37 ± 24.71	992.44 ± 35.46***/‡‡‡	3738.87 ± 31.66***/‡‡‡	3.77 ± 1.00	0.08 ± 0.05	0.30 ± 0.14

^§Parameter (abbreviation, units): the terminal elimination rate constant (λ_z, 1/h), the half-life (T_½, h), the time of maximal concentration (T_max, h), the maximal concentration (C_max, µg/ml), the area under the curve (AUC_0-∞, µg/ml*h), the area under the moment cur (AUMC_0-∞, µg/ml*h²), the mean residence time (MRT_0-∞, h), the total body clearance (Cl_t, (mg/kg)/(µg/ml)/h), and the volume distribution (V_d, (mg/kg)/(µg/ml)).

^¶Drug; Paclitaxel (PTX), Lonidamine (LON)

^#Treatment; Solution (SOL), Targeted Nanoparticles (TAR NP), Nontargeted Nanoparticles (NON NP)

^***p<0.0001,

^**p<0.01,

^*p<0.05 between SOL and either TAR NP or NON NP

^‡‡‡p<0.0001,

^‡‡p<0.01,

^‡p<0.05 between TAR NP and NON NP